CEP-1612 is a proteasome inhibitor responsible for the proteolysis of important cell cycle and apoptosis-regulatory proteins. CEP-1612 helps to induce p21WAF1 and p27KIP1 expression and apoptosis and inhibits tumor growth of the human lung cancer. CEP1612 is a promising candidate for further development as an anticancer drug and demonstrate the feasibility of using proteasome inhibitors as novel antitumor agents. References: Kazi A, Sun J, Doi K, Sung SS, Takahashi Y, Yin H, Rodriguez JM, Becerril J, Berndt N, Hamilton AD, Wang HG, Sebti SM. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. J Biol Chem. 2011 Mar 18;286(11):9382-92. doi: 10.1074/jbc.M110.203638. Epub 2010 Dec 9. PubMed PMID: 21148306; PubMed Central PMCID: PMC3059047.

纯度：≥98%

CAS：189036-01-9